Abeona Therapeutics Inc (NASDAQ:ABEO) – Research analysts at SVB Leerink upped their Q1 2020 EPS estimates for shares of Abeona Therapeutics in a research report issued on Tuesday, March 17th. SVB Leerink analyst M. Foroohar now expects that the biopharmaceutical company will post earnings per share of ($0.24) for the quarter, up from their previous estimate of ($0.33). SVB Leerink also issued estimates for Abeona Therapeutics’ Q2 2020 earnings at ($0.25) EPS, Q3 2020 earnings at ($0.25) EPS, Q4 2020 earnings at ($0.22) EPS, FY2020 earnings at ($0.84) EPS, FY2021 earnings at ($0.88) EPS and FY2022 earnings at ($0.90) EPS.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, March 17th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.01.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 2nd. Cantor Fitzgerald began coverage on Abeona Therapeutics in a report on Tuesday, December 10th. They issued a “hold” rating and a $4.00 price target on the stock. Royal Bank of Canada lowered their target price on Abeona Therapeutics from $14.00 to $11.00 and set an “outperform” rating on the stock in a research report on Wednesday. HC Wainwright began coverage on Abeona Therapeutics in a research report on Tuesday, January 21st. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Mizuho reaffirmed a “hold” rating and issued a $4.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $6.65.
ABEO stock opened at $2.13 on Friday. The business has a fifty day moving average price of $2.81 and a 200 day moving average price of $2.79. Abeona Therapeutics has a fifty-two week low of $1.35 and a fifty-two week high of $8.41. The stock has a market capitalization of $97.19 million, a price-to-earnings ratio of -1.39 and a beta of 1.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 2.45.
Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Abeona Therapeutics in the fourth quarter valued at approximately $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $34,000. Victory Capital Management Inc. boosted its stake in shares of Abeona Therapeutics by 144.5% in the fourth quarter. Victory Capital Management Inc. now owns 11,474 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,782 shares during the period. Zebra Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $50,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Abeona Therapeutics by 42.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 33,613 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 10,088 shares during the period.
In other news, Director Stefano Buono bought 200,000 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The shares were bought at an average price of $2.50 per share, with a total value of $500,000.00. Following the completion of the transaction, the director now owns 270,000 shares of the company’s stock, valued at $675,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.60% of the stock is currently owned by corporate insiders.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company’s lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
